UNC2025, a potent and orally bioavailable MER/FLT3 dual inhibitor

Journal of Medicinal Chemistry

Volumn 57, Issue 16, 2014, Pages 7031-7041

  Zhang, Weihe ^a   Deryckere, Deborah ^c   Hunter, Debra ^b   Liu, Jing ^a   Stashko, Michael A ^a   Minson, Katherine A ^c   Cummings, Christopher T ^c   Lee, Minjung ^c   Glaros, Trevor G ^d   Newton, Dianne L ^d   Sather, Susan ^c   Zhang, Dehui ^a   Kireev, Dmitri ^a   Janzen, William P ^a   Earp, H Shelton ^b   Graham, Douglas K ^c   Frye, Stephen V ^a,b   Wang, Xiaodong ^a  

^a University of North Carolina   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c Children's Hospital Colorado   (United States)

^d FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENINE; CD135 ANTIGEN; FLT3 PROTEIN, HUMAN; MERTK PROTEIN, HUMAN; ONCOPROTEIN; PIPERAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; UNC2025;

ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOAVAILABILITY; DRUG EFFECTS; DRUG SCREENING; HUMAN; IC50; LEUKEMIA, B-CELL; METABOLISM; MOLECULARLY TARGETED THERAPY; ORAL DRUG ADMINISTRATION; PATHOLOGY; SCID MOUSE; STRUCTURE ACTIVITY RELATION; SYNTHESIS; TUMOR CELL LINE;

ADENINE; ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; CELL LINE, TUMOR; CHEMISTRY TECHNIQUES, SYNTHETIC; FMS-LIKE TYROSINE KINASE 3; HUMANS; INHIBITORY CONCENTRATION 50; LEUKEMIA, B-CELL; MICE, SCID; MOLECULAR TARGETED THERAPY; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS; RECEPTOR PROTEIN-TYROSINE KINASES; STRUCTURE-ACTIVITY RELATIONSHIP; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84906878027     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm500749d     Document Type: Article

References (54)

1. Kola, I.; Landis, J. Can the Pharmaceutical Industry Reduce Attrition Rates? Nat. Rev. Drug Discovery 2004, 3 (8) 711-716
2. Palmer, A. M. New Horizons in Drug Metabolism, Pharmacokinetics and Drug Discovery Drug News Perspect. 2003, 16 (1) 57-62
3. Norman, M. H.; Andrews, K. L.; Bo, Y. Y.; Booker, S. K.; Caenepeel, S.; Cee, V. J.; D'Angelo, N. D.; Freeman, D. J.; Herberich, B. J.; Hong, F.-T.; Jackson, C. L. M.; Jiang, J.; Lanman, B. A.; Liu, L.; McCarter, J. D.; Mullady, E. L.; Nishimura, N.; Pettus, L. H.; Reed, A. B.; Miguel, T. S.; Smith, A. L.; Stec, M. M.; Tadesse, S.; Tasker, A.; Aidasani, D.; Zhu, X.; Subramanian, R.; Tamayo, N. A.; Wang, L.; Whittington, D. A.; Wu, B.; Wu, T.; Wurz, R. P.; Yang, K.; Zalameda, L.; Zhang, N.; Hughes, P. E. Selective Class I Phosphoinositide 3-Kinase Inhibitors: Optimization of a Series of Pyridyltriazines Leading to the Identification of a Clinical Candidate, AMG 511 J. Med. Chem. 2012, 55 (17) 7796-7816
4. Barlind, J. G.; Bauer, U. A.; Birch, A. M.; Birtles, S.; Buckett, L. K.; Butlin, R. J.; Davies, R. D. M.; Eriksson, J. W.; Hammond, C. D.; Hovland, R.; Johannesson, P.; Johansson, M. J.; Kemmitt, P. D.; Lindmark, B. T.; Gutierrez, P. M.; Noeske, T. A.; Nordin, A.; O'Donnell, C. J.; Petersson, A. U.; Redzic, A.; Turnbull, A. V.; Vinblad, J. Design and Optimization of Pyrazinecarboxamide- Based Inhibitors of Diacylglycerol Acyltransferase 1 (DGAT1) Leading to a Clinical Candidate Dimethylpyrazinecarboxamide Phenylcyclohexylacetic Acid (AZD7687) J. Med. Chem. 2012, 55 (23) 10610-10629
5. Coteron, J. M.; Marco, M.; Esquivias, J.; Deng, X.; White, K. L.; White, J.; Koltun, M.; El Mazouni, F.; Kokkonda, S.; Katneni, K.; Bhamidipati, R.; Shackleford, D. M.; Angulo-Barturen, I.; Ferrer, S. B.; Belen Jimenez-Diaz, M.; Gamo, F.-J.; Goldsmith, E. J.; Charman, W. N.; Bathurst, I.; Floyd, D.; Matthews, D.; Burrows, J. N.; Rathod, P. K.; Charman, S. A.; Phillips, M. A. Structure-Guided Lead Optimization of Triazolopyrimidine-Ring Substituents Identifies Potent Plasmodium falciparum Dihydroorotate Dehydrogenase Inhibitors with Clinical Candidate Potential J. Med. Chem. 2011, 54 (15) 5540-5561
6. Stepan, A. F.; Mascitti, V.; Beaumont, K.; Kalgutkar, A. S. Metabolism-Guided Drug Design MedChemComm 2013, 4 (4) 631-652
7. St Jean, D. J., Jr.; Fotsch, C. Mitigating Heterocycle Metabolism in Drug Discovery J. Med. Chem. 2012, 55 (13) 6002-6020
8. Chen, J.; Carey, K.; Godowski, P. J. Identification of Gas6 as a Ligand for Mer, a Neural Cell Adhesion Molecule Related Receptor Tyrosine Kinase Implicated in Cellular Transformation Oncogene 1997, 14 (17) 2033-2039
9. Linger, R. M. A.; Keating, A. K.; Earp, H. S.; Graham, D. K. TAM Receptor Tyrosine Kinases: Biologic Functions, Signaling, and Potential Therapeutic Targeting in Human Cancer Adv. Cancer Res. 2008, 100, 35-83
10. Verma, A.; Warner, S. L.; Vankayalapati, H.; Bearss, D. J.; Sharma, S. Targeting Axl and Mer Kinases in Cancer Mol. Cancer Ther. 2011, 10, 1763-1773
11. Graham, D. K.; Salzberg, D. B.; Kurtzberg, J.; Sather, S.; Matsushima, G. K.; Keating, A. K.; Liang, X. Y.; Lovell, M. A.; Williams, S. A.; Dawson, T. L.; Schell, M. J.; Anwar, A. A.; Snodgrass, H. R.; Earp, H. S. Ectopic Expression of the Proto-Oncogene Mer in Pediatric T-Cell Acute Lymphoblastic Leukemia Clin. Cancer Res. 2006, 12 (9) 2662-2669
12. Lee-Sherick, A.; Eisenman, K.; Sather, S.; McGranahan, A.; Armistead, P.; McGary, C.; Hunsucker, S.; Schlegel, J.; Martinson, H.; Cannon, C.; Keating, A. K.; Earp, H. S.; Liang, X.; DeRyckere, D.; Graham, D. K. Aberrant Mer Receptor Tyrosine Kinase Expression Contributes to Leukemogenesis in Acute Myeloid Leukemia Oncogene 2013, 32, 5359-5368
13. Linger, R. M.; Cohen, R. A.; Cummings, C. T.; Sather, S.; Migdall-Wilson, J.; Middleton, D. H.; Lu, X.; Baron, A. E.; Franklin, W. A.; Merrick, D. T.; Jedlicka, P.; Deryckere, D.; Heasley, L. E.; Graham, D. K. Mer or Axl Receptor Tyrosine Kinase Inhibition Promotes Apoptosis, Blocks Growth and Enhances Chemosensitivity of Human Non-Small Cell Lung Cancer Oncogene 2013, 32, 3420-3431
14. Schlegel, J.; Sambade, M. J.; Sather, S.; Moschos, S. J.; Tan, A. C.; Winges, A.; Deryckere, D.; Carson, C. C.; Trembath, D. G.; Tentler, J. J.; Eckhardt, S. G.; Kuan, P. F.; Hamilton, R. L.; Duncan, L. M.; Miller, C. R.; Nikolaishvili-Feinberg, N.; Midkiff, B. R.; Liu, J.; Zhang, W.; Yang, C.; Wang, X.; Frye, S. V.; Earp, H. S.; Shields, J. M.; Graham, D. K. MERTK Receptor Tyrosine Kinase Is a Therapeutic Target in Melanoma J. Clin. Invest. 2013, 123 (5) 2257-2267
15. Tworkoski, K. A.; Platt, J. T.; Bacchiocchi, A.; Bosenberg, M.; Boggon, T. J.; Stern, D. F. MERTK Controls Melanoma Cell Migration and Survival and Differentially Regulates Cell Behavior Relative to AXL Pigm. Cell Melanoma Res. 2013, 26 (4) 527-541
16. Wang, Y.; Moncayo, G.; Morin, P., Jr.; Xue, G.; Grzmil, M.; Lino, M. M.; Clement-Schatlo, V.; Frank, S.; Merlo, A.; Hemmings, B. A. Mer Receptor Tyrosine Kinase Promotes Invasion and Survival in Glioblastoma Multiforme Oncogene 2013, 32 (7) 872-882
17. Rogers, A. E. J.; Le, J. P.; Sather, S.; Pernu, B. M.; Graham, D. K.; Pierce, A. M.; Keating, A. K. Mer Receptor Tyrosine Kinase Inhibition Impedes Glioblastoma Multiforme Migration and Alters Cellular Morphology Oncogene 2012, 31 (38) 4171-4181
18. Keating, A. K.; Salzberg, D. B.; Sather, S.; Liang, X.; Nickoloff, S.; Anwar, A.; Deryckere, D.; Hill, K.; Joung, D.; Sawczyn, K. K.; Park, J.; Curran-Everett, D.; McGavran, L.; Meltesen, L.; Gore, L.; Johnson, G. L.; Graham, D. K. Lymphoblastic Leukemia/Lymphoma in Mice Overexpressing the Mer (MerTK) Receptor Tyrosine Kinase Oncogene 2006, 25 (45) 6092-6100
19. Keating, A. K.; Kim, G. K.; Jones, A. E.; Donson, A. M.; Ware, K.; Mulcahy, J. M.; Salzberg, D. B.; Foreman, N. K.; Liang, X.; Thorburn, A.; Graham, D. K. Inhibition of Mer and Axl Receptor Tyrosine Kinases in Astrocytoma Cells Leads to Increased Apoptosis and Improved Chemosensitivity Mol. Cancer Ther. 2010, 9 (5) 1298-1307
20. Brandao, L.; Winges, A.; Christoph, S.; Sather, S.; Migdall-Wilson, J.; Schlegel, J.; McGranahan, A.; Gao, D.; Liang, X.; DeRyckere, D. Inhibition of MerTK Increases Chemosensitivity and Decreases Oncogenic Potential in T-Cell Acute Lymphoblastic Leukemia Blood Cancer Journal 2013, 3 (1) e101
21. Linger, R. M.; Lee-Sherick, A. B.; Deryckere, D.; Cohen, R. A.; Jacobsen, K. M.; McGranahan, A.; Brandão, L.; Winges, A.; Sawczyn, K. K.; Liang, X.; Keating, A. K.; Tan, A. C.; Earp, H. S.; Graham, D. K. Mer Receptor Tyrosine Kinase Is a Therapeutic Target in Pre-B Cell Acute Lymphoblastic Leukemia Blood 2013, 122, 1599-1609
22. Knubel, K. H.; Pernu, B. M.; Sufit, A.; Nelson, S.; Pierce, A. M.; Keating, A. K. MerTK Inhibition is a Novel Therapeutic Approach for Glioblastoma Multiforme Oncotarget 2014, 5 (5) 1338-1351
23. Abu-Duhier, F. M.; Goodeve, A. C.; Wilson, G. A.; Gari, M. A.; Peake, I. R.; Rees, D. C.; Vandenberghe, E. A.; Winship, P. R.; Reilly, J. T. FLT3 Internal Tandem Duplication Mutations in Adult Acute Myeloid Leukaemia Define a High-Risk Group Br. J. Hamaetol. 2000, 111 (1) 190-195
24. Kottaridis, P. D.; Gale, R. E.; Frew, M. E.; Harrison, G.; Langabeer, S. E.; Belton, A. A.; Walker, H.; Wheatley, K.; Bowen, D. T.; Burnett, A. K.; Goldstone, A. H.; Linch, D. C. The Presence of a FLT3 Internal Tandem Duplication in Patients with Acute Myeloid Leukemia (AML) Adds Important Prognostic Information to Cytogenetic Risk Group and Response to the First Cycle of Chemotherapy: Analysis of 854 Patients from the United Kingdom Medical Research Council AML 10 and 12 Trials Blood 2001, 98 (6) 1752-1759
25. Stone, R. M.; DeAngelo, D. J.; Klimek, V.; Galinsky, I.; Estey, E.; Nimer, S. D.; Grandin, W.; Lebwohl, D.; Wang, Y.; Cohen, P.; Fox, E. A.; Neuberg, D.; Clark, J.; Gilliland, D. G.; Griffin, J. D. Patients with Acute Myeloid Leukemia and an Activating Mutation in FLT3 Respond to a Small-Molecule FLT3 Tyrosine Kinase Inhibitor, PKC412 Blood 2005, 105 (1) 54-60
26. DeAngelo, D. J.; Stone, R. M.; Heaney, M. L.; Nimer, S. D.; Paquette, R. L.; Klisovic, R. B.; Caligiuri, M. A.; Cooper, M. R.; Lecerf, J. M.; Karol, M. D.; Sheng, S.; Holford, N.; Curtin, P. T.; Druker, B. J.; Heinrich, M. C. Phase 1 Clinical Results with Tandutinib (MLN518), a Novel FLT3 Antagonist, In Patients with Acute Myelogenous Leukemia or High-Risk Myelodysplastic Syndrome: Safety, Pharmacokinetics, And Pharmacodynamics Blood 2006, 108 (12) 3674-3681
27. Knapper, S.; Burnett, A. K.; Littlewood, T.; Kell, W. J.; Agrawal, S.; Chopra, R.; Clark, R.; Levis, M. J.; Small, D. A Phase 2 Trial of the FLT3 Inhibitor Lestaurtinib (CEP701) as First-Line Treatment for Older Patients with Acute Myeloid Leukemia Not Considered Fit for Intensive Chemotherapy Blood 2006, 108 (10) 3262-3270
28. Pratz, K. W.; Luger, S. M. Will FLT3 inhibitors fulfill their promise in acute meyloid leukemia? Curr. Opin. Hematol. 2014, 21 (2) 72-78
29. Liu, J.; Yang, C.; Simpson, C.; DeRyckere, D.; Van, D. A.; Miley, M. J.; Kireev, D.; Norris-Drouin, J.; Sather, S.; Hunter, D.; Korboukh, V. K.; Patel, H. S.; Janzen, W. P.; Machius, M.; Johnson, G. L.; Earp, H. S.; Graham, D. K.; Frye, S. V.; Wang, X. Discovery of Small Molecule Mer Kinase Inhibitors for the Treatment of Pediatric Acute Lymphoblastic Leukemia ACS Med. Chem. Lett. 2012, 3, 129-134
30. Liu, J.; Zhang, W.; Stashko, M. A.; DeRyckere, D.; Cummings, C. T.; Hunter, D.; Yang, C.; Jayakody, C. N.; Cheng, N.; Simpson, C.; Norris-Drouin, J.; Sather, S.; Kireev, D.; Janzen, W. P.; Earp, H. S.; Graham, D. K.; Frye, S. V.; Wang, X. UNC1062, a New and Potent Mer Inhibitor Eur. J. Med. Chem. 2013, 65, 83-93
31. Zhang, W.; Zhang, D.; Stashko, M. A.; DeRyckere, D.; Hunter, D.; Kireev, D.; Miley, M. J.; Cummings, C.; Lee, M.; Norris-Drouin, J.; Stewart, W. M.; Sather, S.; Zhou, Y.; Kirkpatrick, G.; Machius, M.; Janzen, W. P.; Earp, H. S.; Graham, D. K.; Frye, S. V.; Wang, X. Pseudo-Cyclization through Intramolecular Hydrogen Bond Enables Discovery of Pyridine Substituted Pyrimidines as New Mer Kinase Inhibitors J. Med. Chem. 2013, 56 (23) 9683-9692
32. Zhang, W.; McIver, A. L.; Stashko, M. A.; Deryckere, D.; Branchford, B. R.; Hunter, D.; Kireev, D.; Miley, M. J.; Norris-Drouin, J.; Stewart, W. M.; Lee, M.; Sather, S.; Zhou, Y.; Di Paola, J. A.; Machius, M.; Janzen, W. P.; Earp, H. S.; Graham, D. K.; Frye, S. V.; Wang, X. Discovery of mer Specific Tyrosine Kinase Inhibitors for the Treatment and Prevention of Thrombosis J. Med. Chem. 2013, 56 (23) 9693-9700
33. Huang, X.; Finerty, P., Jr.; Walker, J. R.; Butler-Cole, C.; Vedadi, M.; Schapira, M.; Parker, S. A.; Turk, B. E.; Thompson, D. A.; Dhe-Paganon, S. Structural Insights into the Inhibited States of the Mer Receptor Tyrosine Kinase J. Struct Biol. 2009, 165 (2) 88-96
34. Greshock, J.; Bachman, K. E.; Degenhardt, Y. Y.; Jing, J.; Wen, Y. H.; Eastman, S.; McNeil, E.; Moy, C.; Wegrzyn, R.; Auger, K.; Hardwicke, M. A.; Wooster, R. Molecular Target Class Is Predictive of In vitro Response Profile Cancer Res. 2010, 70 (9) 3677-3686
35. Howard, S.; Berdini, V.; Boulstridge, J. A.; Carr, M. G.; Cross, D. M.; Curry, J.; Devine, L. A.; Early, T. R.; Fazal, L.; Gill, A. L.; Heathcote, M.; Maman, S.; Matthews, J. E.; McMenamin, R. L.; Navarro, E. F.; O'Brien, M. A.; O'Reilly, M.; Rees, D. C.; Reule, M.; Tisi, D.; Williams, G.; Vinkovic, M.; Wyatt, P. G. Fragment-Based Discovery of the Pyrazol-4-yl urea (AT9283), a Multitargeted Kinase Inhibitor with Potent Aurora Kinase Activity J. Med. Chem. 2009, 52 (2) 379-388
36. Schroeder, G. M.; An, Y.; Cai, Z. W.; Chen, X. T.; Clark, C.; Cornelius, L. A.; Dai, J.; Gullo-Brown, J.; Gupta, A.; Henley, B.; Hunt, J. T.; Jeyaseelan, R.; Kamath, A.; Kim, K.; Lippy, J.; Lombardo, L. J.; Manne, V.; Oppenheimer, S.; Sack, J. S.; Schmidt, R. J.; Shen, G.; Stefanski, K.; Tokarski, J. S.; Trainor, G. L.; Wautlet, B. S.; Wei, D.; Williams, D. K.; Zhang, Y.; Fargnoli, J.; Borzilleri, R. M. Discovery of N -(4-(2-amino-3-chloropyridin-4-yloxy)-3- fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3- carboxamide (BMS-777607), a Selective and Orally Efficacious Inhibitor of the Met Kinase Superfamily J. Med. Chem. 2009, 52 (5) 1251-1254
37. Kataoka, Y.; Mukohara, T.; Tomioka, H.; Funakoshi, Y.; Kiyota, N.; Fujiwara, Y.; Yashiro, M.; Hirakawa, K.; Hirai, M.; Minami, H. Foretinib (GSK1363089), a Multi-Kinase Inhibitor of MET and VEGFRs, Inhibits Growth of Gastric Cancer Cell Lines by Blocking Inter-Receptor Tyrosine Kinase Networks Invest. New Drugs 2012, 30 (4) 1352-1360
38. Yan, S. B.; Peek, V. L.; Ajamie, R.; Buchanan, S. G.; Graff, J. R.; Heidler, S. A.; Hui, Y. H.; Huss, K. L.; Konicek, B. W.; Manro, J. R.; Shih, C.; Stewart, J. A.; Stewart, T. R.; Stout, S. L.; Uhlik, M. T.; Um, S. L.; Wang, Y.; Wu, W.; Yan, L.; Yang, W. J.; Zhong, B.; Walgren, R. A. LY2801653 is an Orally Bioavailable Multi-Kinase Inhibitor with Potent Activity against MET, MST1R, and Other Oncoproteins, And Displays Anti-Tumor Activities in Mouse Xenograft Models Invest. New Drugs 2013, 31 (4) 833-844
39. Katz, J. D.; Jewell, J. P.; Guerin, D. J.; Lim, J.; Dinsmore, C. J.; Deshmukh, S. V.; Pan, B. S.; Marshall, C. G.; Lu, W.; Altman, M. D.; Dahlberg, W. K.; Davis, L.; Falcone, D.; Gabarda, A. E.; Hang, G.; Hatch, H.; Holmes, R.; Kunii, K.; Lumb, K. J.; Lutterbach, B.; Mathvink, R.; Nazef, N.; Patel, S. B.; Qu, X.; Reilly, J. F.; Rickert, K. W.; Rosenstein, C.; Soisson, S. M.; Spencer, K. B.; Szewczak, A. A.; Walker, D.; Wang, W.; Young, J.; Zeng, Q. Discovery of a 5H-Benzo[4,5]cyclohepta[1,2-b]pyridin-5-one (MK-2461) Inhibitor of c-Met Kinase for the Treatment of Cancer J. Med. Chem. 2011, 54 (12) 4092-4108
40. Frye, S. V. The Art of the Chemical Probe Nat. Chem. Biol. 2010, 6 (3) 159-161
41. Liu, J.; Wang, X. Microwave-Assisted, Divergent Solution-Phase Synthesis of 1,3,6-Trisubstituted Pyrazolo[3,4-d]pyrimidines ACS Comb. Sci. 2011, 13 (4) 414-420
42. Palmer, D. S.; McDonagh, J. L.; Mitchell, J. B.; van Mourik, T.; Fedorov, M. V. First-Principles Calculation of the Intrinsic Aqueous Solubility of Crystalline Druglike Molecules J. Chem. Theory Comput. 2012, 8 (9) 3322-3337
43. Veith, H.; Southall, N.; Huang, R.; James, T.; Fayne, D.; Artemenko, N.; Shen, M.; Inglese, J.; Austin, C. P.; Lloyd, D. G.; Auld, D. S. Comprehensive Characterization of Cytochrome P450 Isozyme Selectivity Across Chemical Libraries Nat. Biotechnol. 2009, 27 (11) 1050-1055
44. Diana, G. D.; Rudewicz, P.; Pevear, D. C.; Nitz, T. J.; Aldous, S. C.; Aldous, D. J.; Robinson, D. T.; Draper, T.; Dutko, F. J. Picornavirus Inhibitors: Trifluoromethyl Substitution Provides a Global Protective Effect against Hepatic Metabolism J. Med. Chem. 1995, 38 (8) 1355-1371
45. Meanwell, N. A. Synopsis of Some Recent Tactical Application of Bioisosteres in Drug Design J. Med. Chem. 2011, 54 (8) 2529-2591
46. Bach, R. D.; Dmitrenko, O. Strain Energy of Small Ring Hydrocarbons. Influence of C-H Bond Dissociation Energies J. Am. Chem. Soc. 2004, 126 (13) 4444-4452
47. V600E. Part 3: An Increase in Aqueous Solubility via the Disruption of Crystal Packing Bioorg. Med. Chem. Lett. 2012, 22 (2) 912-915
48. Schuürer, S. C.; Muskal, S. M. Kinome-Wide Activity Modeling from Diverse Public High-Quality Data Sets J. Chem. Inf. Model. 2013, 53 (1) 27-38
49. Kitagawa, D.; Yokota, K.; Gouda, M.; Narumi, Y.; Ohmoto, H.; Nishiwaki, E.; Akita, K.; Kirii, Y. Activity-Based Kinase Profiling of Approved Tyrosine Kinase Inhibitors Genes Cells 2013, 18 (2) 110-122
50. Anastassiadis, T.; Deacon, S. W.; Devarajan, K.; Ma, H.; Peterson, J. R. Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity Nat. Biotechnol. 2011, 29 (11) 1039-1045
51. Morrison, J. F. Kinetics of the Reversible Inhibition of Enzyme-Catalysed Reactions by Tight-Binding Inhibitors Biochim. Biophys. Acta 1969, 185 (2) 269-286
52. Copeland, R. A. Evaluation of Enzyme Inhibitors in Drug Discovery. A guide for Medicinal Chemists and Pharmacologists Methods Biochem. Anal. 2005, 46, 178-189
53. Patricelli, M. P.; Nomanbhoy, T. K.; Wu, J.; Brown, H.; Zhou, D.; Zhang, J.; Jagannathan, S.; Aban, A.; Okerberg, E.; Herring, C.; Nordin, B.; Weissig, H.; Yang, Q.; Lee, J. D.; Gray, N. S.; Kozarich, J. W. In Situ Kinase Profiling Reveals Functionally Relevant Properties of Native Kinases Chem. Biol. 2011, 18 (6) 699-710
54. Walters, D. K.; Stoffregen, E. P.; Heinrich, M. C.; Deininger, M. W.; Druker, B. J. RNAi-Induced down-Regulation of FLT3 Expression in AML Cell Lines Increases Sensitivity to MLN518 Blood 2005, 105 (7) 2952-2954